Citius Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CTXR Nasdaq 8731 https://www.citiuspharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Citius Pharmaceuticals Inc

Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company - Mar 30th, 2023 12:30 pm
When Will Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Breakeven? - Mar 27th, 2023 1:52 pm
Citius Pharmaceuticals Confirms No Exposure to Silicon Valley Bank - Mar 13th, 2023 1:15 pm
Citius Pharmaceuticals to Participate in the 35th Annual Roth Conference - Mar 8th, 2023 1:30 pm
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update - Feb 10th, 2023 9:30 pm
Here Are 2 Ways I'm Playing the Market With Small-Cap Stocks - Feb 6th, 2023 3:30 pm
Sidoti's January Micro-Cap Conference - Jan 17th, 2023 3:00 pm
Here's Why We're Not Too Worried About Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation - Jan 16th, 2023 12:09 pm
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023 - Jan 11th, 2023 1:30 pm
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR) - Dec 28th, 2022 2:35 pm
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update - Dec 22nd, 2022 9:30 pm
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma - Dec 1st, 2022 12:30 pm
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program - Nov 21st, 2022 1:00 pm
Citius Pharmaceuticals Announces Efficacy and Safety Data for its I/ONTAK (E7777) Phase 3 Study for Treatment of Cutaneous T-Cell Lymphoma to be Presented at the 64th American Society of Hematology (ASH) Annual Meeting - Nov 9th, 2022 1:30 pm
Citius Pharmaceuticals to Present at the ThinkEquity Conference on October 26, 2022 - Oct 18th, 2022 12:30 pm
Citius Pharmaceuticals, Inc.'s (NASDAQ:CTXR) Profit Outlook - Oct 18th, 2022 11:59 am
Citius Pharmaceuticals to Present at Dawson James Securities Small Cap Growth Conference on October 12, 2022 - Oct 6th, 2022 8:30 pm
Citius Pharmaceuticals, Inc. Submits Biologics License Application to the U.S. Food and Drug Administration for Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma - Sep 28th, 2022 12:30 pm
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings - Sep 23rd, 2022 10:48 am
Citius Pharmaceuticals Announces a Clinical Collaboration with the University of Pittsburgh to Evaluate T-reg Cell Depletion with I/ONTAK (E7777) in Combination with Pembrolizumab in Recurrent or Metastatic Solid Cancer Tumors in a Phase 1 Investigator-Initiated Trial - Sep 22nd, 2022 8:30 pm